Home / Peptide legality / By country / Australia
Are peptides legal in Australia?
Peptides are legal in Australia only as TGA-approved or lawfully prescribed prescription medicines, unapproved 'research' peptides such as BPC-157 and TB-500 are not on the Australian Register of Therapeutic Goods and cannot lawfully be imported for sale, advertised or supplied for human use, with the TGA warning it will use seizures, infringement notices, civil penalties and criminal prosecution.
Legal status overview
Peptides are restricted in Australia rather than freely legal: lawful access runs through a prescription and an approved or lawfully compounded medicine, while unapproved peptide products are unlawful to import commercially, advertise or supply. The Therapeutic Goods Administration (TGA), operating under the Therapeutic Goods Act 1989, treats all peptide products as therapeutic goods, so any peptide not entered on the Australian Register of Therapeutic Goods (ARTG) is an 'unapproved' good. Since 2024 the Commonwealth has also banned pharmacy compounding of GLP-1 receptor agonists such as semaglutide and tirzepatide, and in 2026 the TGA made unapproved peptides a priority compliance area. Prescribers and compounders additionally answer to Ahpra and state/territory medicines law.
Key points
- Under the Therapeutic Goods Act 1989, all peptide products are regulated as therapeutic goods in Australia, and any peptide not included on the Australian Register of Therapeutic Goods (ARTG) is an 'unapproved' product. [1]
- The TGA states it is illegal to intentionally import, export, manufacture or supply unregulated therapeutic goods in Australia, including unapproved peptides, and reports adverse events such as severe allergic reactions from these products. [10]
- Individuals in Australia may personally import a prescription-only medicine under the TGA's Personal Importation Scheme only if they hold a valid Australian prescription at the time of import, the quantity is no more than a three-month supply at the maximum prescribed dose (and no more than a 15-month supply in any 12 months), and the product is not sold, supplied or given to anyone outside the importer's immediate family. [3]
- The TGA warns Australian consumers about the risks of importing unapproved peptide products and says it continues to see such products arriving through the Personal Importation Scheme. [2]
- Enforcement in Australia is escalating: the TGA has made unapproved peptide products a priority focus area and says offenders may face warning letters, infringement notices, product seizures and forfeiture, civil penalties and, in serious cases, criminal prosecution, with unlabelled vials increasingly intercepted at the border. [4]
- Australia banned pharmacy compounding of GLP-1 receptor agonists including semaglutide and tirzepatide, announced by Health Minister Mark Butler in May 2024 and taking effect from 1 October 2024. [7]
- The legal pathway to peptides in Australia is a consultation with a qualified health professional and supply through an Australian pharmacy, the TGA strongly advises Australians not to buy unapproved peptide products online or from overseas. [5]
- Australian health practitioners who prescribe, compound or supply unapproved peptide products must still meet all Commonwealth and state/territory legislative requirements plus professional standards set by Ahpra. [1]
Compound-by-compound status
| BPC-157 | BPC-157 has no TGA-approved product in Australia and therefore falls within the TGA's 'unapproved peptide product' category that cannot lawfully be imported for supply, advertised or sold for human use; no BPC-157-specific Australian scheduling entry was located in this research, so this reflects the general unapproved-peptide framework rather than a named BPC-157 ruling. [1] |
|---|---|
| Semaglutide / tirzepatide (GLP-1 class) | Semaglutide is legal in Australia only as a TGA-approved prescription medicine, Novo Nordisk's Ozempic® and Wegovy® are the only TGA-approved semaglutide products, and compounded semaglutide-like products offered by telehealth providers are unapproved therapeutic goods. [6] |
| Compounded GLP-1 weight-loss copies | Compounded 'replica' semaglutide and tirzepatide are banned in Australia from 1 October 2024, after the federal government moved against compounding pharmacies supplying an estimated 20,000 Australians. [7] |
| TB-500 (thymosin beta-4) | TB-500 (thymosin beta-4) is an unapproved peptide in Australia and is prohibited in sport, with possession or use by athletes capable of triggering an Anti-Doping Rule Violation and a ban from sport, per Sport Integrity Australia. [9] |
| Human growth hormone (somatropin/HGH) | No Australia-specific primary source on somatropin's scheduling was retrieved in this research; HGH products lawfully available in Australia are prescription medicines on the ARTG, while non-ARTG HGH-related peptides fall under the TGA's unapproved-peptide framework, treat the somatropin-specific detail as unverified here. (no source found) |
Frequently asked questions
Can I buy peptides in Australia without a prescription?
No, in Australia peptides are therapeutic goods, and the TGA advises consumers to use only products supplied through Australian pharmacies after advice from a qualified health professional, not unapproved peptides bought online or from overseas. [5]
Is it legal to import peptides into Australia for personal use?
Only under strict conditions: Australia's Personal Importation Scheme requires a valid Australian prescription for any prescription-only medicine at the time of import, caps the order at a three-month supply at the maximum prescribed dose (15-month supply per 12 months), and forbids selling or giving the product to others. The TGA separately warns that unapproved peptide products imported this way carry serious safety and compliance risks. [3]
What are the penalties for selling unapproved peptides in Australia?
Sellers and promoters of unapproved peptides in Australia risk warning letters, infringement notices, product seizure and forfeiture, civil penalties and, in serious cases, criminal prosecution, with the TGA also working with social media and e-commerce platforms to remove unlawful advertising. [4]
Can a telehealth provider or compounding pharmacy in Australia prescribe compounded semaglutide for weight loss?
No, compounding of GLP-1 receptor agonists such as semaglutide and tirzepatide has been banned in Australia since 1 October 2024, and the TGA had already flagged telehealth-supplied compounded semaglutide-like products as unapproved therapeutic goods. [7]
Has the TGA actually taken action against peptide and compounded weight-loss suppliers in Australia?
Yes, in February 2024 the TGA raided Victorian pharmacy Como Compounding and seized vials of compounded semaglutide it alleged were unlawfully manufactured, and by 2026 the TGA had expanded its priority compliance focus to unapproved peptide products generally. [8]
Sources
- Therapeutic Goods Administration, Understanding your responsibilities when importing, compounding and supplying unapproved peptide products (retrieved 2026-09-22)
- Therapeutic Goods Administration, TGA warning on the risks of importing unapproved peptide products (retrieved 2026-09-22)
- Therapeutic Goods Administration, Personal Importation Scheme (retrieved 2026-09-22)
- Therapeutic Goods Administration, Unapproved peptide product promoters and suppliers are put on notice (retrieved 2026-09-22)
- Therapeutic Goods Administration, Concerns regarding the public health risks associated with unapproved peptide products (retrieved 2026-09-22)
- Therapeutic Goods Administration, Compounding safety information: semaglutide products (retrieved 2026-09-22)
- The Medical Republic, Butler slaps ban on compounded semaglutide and tirzepatide (retrieved 2026-09-22)
- ABC News, Government bans replicas of weight loss drug Ozempic®, as vision of raid on filthy lab released (retrieved 2026-09-22)
- Sport Integrity Australia, Peptides Explained (retrieved 2026-09-22)
- ABC News, TGA issues alert over risks of unregulated peptides (retrieved 2026-09-22)
- Therapeutic Goods Administration, Update: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) pharmacy compounding changes (retrieved 2026-09-22)
Last researched: 2026-09-22.